August 9-13, 2021 (Hybrid Conference)

ⓘ New this year! We will offer the opportunity to attend in-person or via web stream.

For the safety of our participants, the University of Nebraska Medical Center and Nebraska Medicine have decided to host a hybrid 2021 Pan Pacific Lymphoma Conference. For those attending in-person, UNMC/Nebraska Medicine and the Fairmont Orchid are committed to enhanced levels of cleanliness, attendance limits and physical distancing meeting protocols. Mandatory masks and COVID rapid check verifications may be required prior to joining the conference. For attendees who are not able to travel, a virtual option with live web streaming is available.

IMPORTANT: As the pandemic continues to evolve, if we are not able to conduct this conference in-person, we will convert the entire conference to a virtual/web stream conference.

UPDATE:  The State of Hawai'i's vaccination exception program for domestic, Hawai'i-bound travelers vaccinated in the United States or U.S. Territories will allow travelers to bypass the state's quarantine requirement with proof of vaccination beginning July 8, 2021.  More instructions will be provided to all pre-registrants.

More Than 25 Years of Educational Excellence

The Pan Pacific Lymphoma Conference is one of the largest gatherings of clinicians and researchers specializing in the areas of lymphoma and transplantation. The 2021 conference is your chance to explore vital information on clinical updates and research, meet key thought leaders, and exchange ideas with more than 600 members of the multidisciplinary lymphoma clinical team including oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists.

Conference Venue

Fairmont Orchid 1 North Kaniku Drive Kohala Coast, HI 96743 Telephone: 1-808-885-2000 Make your reservation for the conference Go to the Fairmont Orchid main website for hotel information

Conference Objectives

At the conclusion of the conference, the attendee should be better able to:

1. Discuss patient and disease-related factors that impact the diagnosis, prognosis, and approaches to treatment of hematologic malignancies, including lymphoma, myeloma, leukemia
2. Assess clinical trial data of current and emerging agents and regimens that impact management strategies for patients with Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL)
3. Describe currently available and novel investigational strategies for the treatment and maintenance of patients with multiple myeloma (MM)
4. Evaluate results of clinical trials investigating treatment approaches for patients with acute and chronic leukemias
5. Develop strategies to integrate emerging therapeutic strategies into the armamentarium for patients with hematologic malignancies
6. Identify factors that improve patient quality-of-life including appropriate patient counseling and mitigating treatment-related adverse events
7. Analyze factors that impact enrollment of patients with lymphoma, leukemia and myeloma into clinical trials examining novel treatment approaches
8. Explain the roles of the interprofessional health care team in the diagnosis, treatment, management and support of lymphoma and hematologic malignancies

Conference Directors

	James O. Armitage, MD Joe Shapiro Professor of Medicine Division of Oncology and Hematology Department of Internal Medicine University of Nebraska Medical Center
	Matthew A. Lunning, DO, FACP Associate Professor Division of Oncology and Hematology Department of Internal Medicine University of Nebraska Medical Center
	Robbe L. Peetz, MMS, PA-C Advanced Practice Provider Manager Cancer Services Nebraska Medicine
	Tawny J. Roeder, RN, BSN, BMTCN Case Manager, Blood and Marrow Transplantation Division of Oncology and Hematology Department of Internal Medicine Nebraska Medicine
	Julie M. Vose, MD, MBA Neumann M. and Mildred E. Harris Professor Chief, Division of Oncology and Hematology Department of Internal Medicine University of Nebraska Medical Center

Continuing Education Credits

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

The University of Nebraska Medical Center designates this live activity for a maximum of 29.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

The University of Nebraska Medical Center designates this activity for up to 29.25 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Pharmacists

The University of Nebraska Medical Center designates this activity for 29.25 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 29 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Sponsors

This conference is sponsored by the UNMC Department of Internal Medicine – Division of Oncology and Hematology, with the UNMC College of Nursing Continuing Nursing Education and UNMC Center for Continuing Education.

For More Information

Contact Brenda Ram, CMP, CHCP via email or call 402-559-9250.